Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLFSNASDAQ:IRTCNASDAQ:PRCTNASDAQ:SLNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLFSBioLife Solutions$22.26+2.2%$23.07$18.70▼$29.55$1.06B2.01386,081 shs425,920 shsIRTCiRhythm Technologies$146.37+2.6%$116.34$55.92▼$146.58$4.67B1.34475,850 shs263,470 shsPRCTPROCEPT BioRobotics$58.53+2.0%$55.28$47.04▼$103.81$3.24B1.1818,908 shs916,317 shsSLNOSoleno Therapeutics$76.26-0.8%$70.00$36.93▼$80.99$3.87B-2.67748,362 shs569,452 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLFSBioLife Solutions+2.20%-2.41%-10.78%-11.47%+2.49%IRTCiRhythm Technologies+2.58%+3.65%+38.10%+33.77%+64.57%PRCTPROCEPT BioRobotics+2.00%-1.10%+11.51%-14.07%-12.51%SLNOSoleno Therapeutics-0.82%+1.61%+4.10%+69.09%+85.28%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLFSBioLife Solutions2.4129 of 5 stars3.51.00.00.03.52.50.6IRTCiRhythm Technologies1.3016 of 5 stars2.52.00.00.04.00.00.6PRCTPROCEPT BioRobotics2.6375 of 5 stars3.42.00.00.03.62.50.6SLNOSoleno Therapeutics4.8524 of 5 stars4.64.00.04.62.93.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLFSBioLife Solutions 3.00Buy$31.1740.01% UpsideIRTCiRhythm Technologies 2.91Moderate Buy$133.73-8.64% DownsidePRCTPROCEPT BioRobotics 2.86Moderate Buy$90.0053.77% UpsideSLNOSoleno Therapeutics 3.11Buy$106.7840.02% UpsideCurrent Analyst Ratings BreakdownLatest BLFS, SLNO, IRTC, and PRCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025IRTCiRhythm TechnologiesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$130.00 ➝ $167.005/13/2025BLFSBioLife SolutionsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/8/2025SLNOSoleno TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$81.00 ➝ $97.005/8/2025SLNOSoleno TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$102.00 ➝ $105.005/2/2025IRTCiRhythm TechnologiesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$152.00 ➝ $139.005/2/2025IRTCiRhythm TechnologiesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$133.00 ➝ $150.005/2/2025IRTCiRhythm TechnologiesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$104.00 ➝ $130.005/2/2025IRTCiRhythm TechnologiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$138.00 ➝ $151.004/25/2025PRCTPROCEPT BioRoboticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$104.00 ➝ $84.004/24/2025SLNOSoleno TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$93.00 ➝ $145.004/15/2025SLNOSoleno TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLFSBioLife Solutions$87.76M12.05N/AN/A$7.67 per share2.90IRTCiRhythm Technologies$618.59M7.55N/AN/A$6.85 per share21.37PRCTPROCEPT BioRobotics$249.12M13.00N/AN/A$5.56 per share10.53SLNOSoleno TherapeuticsN/AN/AN/AN/A$5.16 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLFSBioLife Solutions-$66.43M-$0.29N/AN/AN/A-38.98%-6.61%-5.54%8/14/2025 (Estimated)IRTCiRhythm Technologies-$123.41M-$3.14N/AN/AN/A-19.14%-118.83%-11.34%8/7/2025 (Estimated)PRCTPROCEPT BioRobotics-$105.90M-$1.70N/AN/AN/A-50.07%-38.57%-26.06%8/7/2025 (Estimated)SLNOSoleno Therapeutics-$38.99M-$4.62N/AN/AN/AN/A-61.99%-55.21%8/6/2025 (Estimated)Latest BLFS, SLNO, IRTC, and PRCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025BLFSBioLife Solutions-$0.03$0.04+$0.07-$0.01$22.22 million$23.94 million5/7/2025Q1 2025SLNOSoleno Therapeutics-$1.14-$0.95+$0.19-$0.95N/AN/A5/1/2025Q1 2025IRTCiRhythm Technologies-$0.89-$0.95-$0.06-$0.97$153.39 million$158.68 million4/24/2025Q1 2025PRCTPROCEPT BioRobotics-$0.49-$0.45+$0.04-$0.45$65.39 million$69.16 million3/5/2025Q4 2024SLNOSoleno Therapeutics-$0.86-$1.27-$0.41-$1.27N/AN/A3/3/2025Q4 2024BLFSBioLife Solutions-$0.06$0.26+$0.32$0.26$21.73 million$22.71 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLFSBioLife SolutionsN/AN/AN/AN/AN/AIRTCiRhythm TechnologiesN/AN/AN/AN/AN/APRCTPROCEPT BioRoboticsN/AN/AN/AN/AN/ASLNOSoleno TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLFSBioLife Solutions0.032.781.78IRTCiRhythm Technologies9.006.276.12PRCTPROCEPT BioRobotics0.216.025.07SLNOSoleno TherapeuticsN/A17.2617.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLFSBioLife Solutions93.24%IRTCiRhythm TechnologiesN/APRCTPROCEPT BioRobotics89.46%SLNOSoleno Therapeutics97.42%Insider OwnershipCompanyInsider OwnershipBLFSBioLife Solutions2.20%IRTCiRhythm Technologies1.10%PRCTPROCEPT BioRobotics6.60%SLNOSoleno Therapeutics12.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLFSBioLife Solutions44047.50 million45.37 millionOptionableIRTCiRhythm Technologies1,79031.93 million31.09 millionOptionablePRCTPROCEPT BioRobotics43055.33 million43.10 millionOptionableSLNOSoleno Therapeutics3050.39 million37.81 millionOptionableBLFS, SLNO, IRTC, and PRCT HeadlinesRecent News About These CompaniesQ2 EPS Estimate for Soleno Therapeutics Boosted by AnalystMay 27 at 2:07 AM | marketbeat.comHC Wainwright Issues Optimistic Estimate for SLNO EarningsMay 27 at 1:57 AM | americanbankingnews.comToronto Dominion Bank Makes New $1.17 Million Investment in Soleno Therapeutics, Inc. (NASDAQ:SLNO)May 26 at 4:16 AM | marketbeat.comSoleno Therapeutics seeking regulatory approval in treatment of PWSMay 24, 2025 | finance.yahoo.comSoleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XRMay 24, 2025 | finance.yahoo.comSoleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XRMay 24, 2025 | finance.yahoo.comWoodline Partners LP Reduces Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO)May 24, 2025 | marketbeat.comSoleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of ...May 23, 2025 | finance.yahoo.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Sold by Frazier Life Sciences Management L.P.May 23, 2025 | marketbeat.comSoleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XRMay 23, 2025 | insidermonkey.comBrokerages Set Soleno Therapeutics, Inc. (NASDAQ:SLNO) Target Price at $106.78May 23, 2025 | americanbankingnews.comSoleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi SyndromeMay 22, 2025 | globenewswire.comNationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Acquires Shares of 299,244 Soleno Therapeutics, Inc. (NASDAQ:SLNO)May 22, 2025 | marketbeat.comUnion Square Park Capital Management LLC Acquires Shares of 50,000 Soleno Therapeutics, Inc. (NASDAQ:SLNO)May 22, 2025 | marketbeat.comRafferty Asset Management LLC Acquires 9,847 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)May 22, 2025 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Average Recommendation of "Buy" from BrokeragesMay 22, 2025 | marketbeat.comSoleno Therapeutics to Participate in Upcoming June ConferencesMay 21, 2025 | santelog.comSoleno Therapeutics Presents Positive Clinical Data for VYKAT™ XR at the 2025 Pediatric Endocrine Society Annual MeetingMay 21, 2025 | nasdaq.comVestal Point Capital LP Buys 340,000 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)May 21, 2025 | marketbeat.comDeutsche Bank AG Purchases 36,971 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)May 21, 2025 | marketbeat.comSoleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi SyndromeMay 20, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBLFS, SLNO, IRTC, and PRCT Company DescriptionsBioLife Solutions NASDAQ:BLFS$22.26 +0.48 (+2.20%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$22.24 -0.02 (-0.07%) As of 05/27/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.iRhythm Technologies NASDAQ:IRTC$146.37 +3.68 (+2.58%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$144.57 -1.80 (-1.23%) As of 05/27/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.PROCEPT BioRobotics NASDAQ:PRCT$58.53 +1.15 (+2.00%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$58.98 +0.45 (+0.76%) As of 05/27/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.Soleno Therapeutics NASDAQ:SLNO$76.26 -0.63 (-0.82%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$76.26 -0.01 (-0.01%) As of 05/27/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
